**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 50130

**Manuscript Type:** CASE REPORT

**Alagille syndrome associated with total anomalous pulmonary venous connection and severe xanthomas: A case report**

Zeng HS *et al*. ALGS with TAPVC and severe xanthomas

Han-Shi Zeng, Zhan-Hui Zhang, Yan Hu, Gui-Lang Zheng, Jing Wang, Jing-Wen Zhang, Yu-Xiong Guo

**Han-Shi Zeng, Yan Hu, Gui-Lang Zheng, Jing Wang, Jing-Wen Zhang, Yu-Xiong Guo,** Department of Pediatrics, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510030, Guangdong Province, China

**Zhan-Hui Zhang,** Department of Pediatrics, Clinical Medicine Research Institute, The First Affiliated Hospital, Jinan University, Guangzhou 510630, Guangdong Province, China

**Author contributions:** Zeng HS conducted data curation and wrote the manuscript; Guo YX revised and approved the final manuscript; all authors contributed to the article and approved the submitted version.

**Corresponding author: Yu-Xiong Guo, MD, Associate Professor,** Department of Pediatrics, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, No. 106 Zhongshan Road, Guangzhou 510030, Guangdong Province, China. 2003kellylaw@163.com

**Received:** November 24, 2021

**Revised:** June 13, 2022

**Accepted: July 11, 2022**

**Published online:**

**Abstract**

BACKGROUND

Alagille syndrome (ALGS) is an autosomal dominant genetic disorder caused by mutations in the *JAG1* or *NOTCH2* gene. It is characterized by decreased intrahepatic bile ducts associated with a variety of abnormalities in many other organ systems, such as the cardiovascular, skeletal, and urinary systems.

CASE SUMMARY

We report a rare case of ALGS. A 1-month-old male infant presented with sustained jaundice and had a rare congenital heart disease: Total anomalous pulmonary venous connection (TAPVC). Sustained jaundice, particularly with cardiac murmur, caught our attention. Laboratory tests revealed elevated levels of alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transpeptidase, total bilirubin, and total bile acids, indicating serious intrahepatic cholestasis. Imaging confirmed the presence of butterfly vertebra at the seventh thoracic vertebra. This suggested ALGS, which was confirmed by genetic testing with a c.3197dupC mutation in the *JAG1* gene. Ursodiol was administered immediately after confirmation of the diagnosis, and cardiac surgery was performed when the patient was 1.5 month old. He recovered well after treatment and was discharged at the age of 3 mo. At the age of two years, the patient returned to our clinic because multiple cutaneous nodules with xanthomas appeared, and their size and number increased over time.

CONCLUSION

We report a unique case of ALGS associated with TAPVC and severe xanthomas. This study has enriched the clinical manifestations of ALGS and emphasized the association between *JAG1* gene and TAPVC.

**Key Words:** Alagille syndrome; *JAG1* gene; Notch signaling pathway; Total anomalous pulmonary venous connection; Severe xanthomas; Case report

Zeng HS, Zhang ZH, Hu Y, Zheng GL, Wang J, Zhang JW, Guo YX. Alagille syndrome associated with total anomalous pulmonary venous connection and severe xanthomas: A case report. *World J Clin Cases* 2022; In press

**Core Tip:** Total anomalous pulmonary venous connection (TAPVC) and severe xanthomas are rarely reported in Alagille syndrome (ALGS) patients. These two symptoms have never appeared in the same patient at the same time. Here, we report a unique case of ALGS associated with TAPVC and severe xanthomas. This study has enriched the clinical manifestations of ALGS and emphasized the association between *JAG1* gene and TAPVC.

**INTRODUCTION**

Alagille syndrome (ALGS, OMIM 118450) is a multiple system disorder that affects the face, eyes, liver, heart, bones and other organs[1-3]. ALGS is due to biallelic mutations in the Notch signaling pathway ligand JAG1 (JAGGED1) in 94% of patients and Notch receptors (NOTCH2) in 1%–2% of patients[4-6]. ALGS can be clinically diagnosed if three of the following features are present: Cardiac murmur, posterior embryotoxon (eye abnormalities), butterfly-like vertebrae, renal abnormalities, and characteristic faces in the presence of bile duct paucity on liver biopsy[7,8]; or at least 4 of the 5 major features if liver biopsy is not performed[9,10]. In some atypical cases, molecular confirmation of ALGS diagnosis is valuable[7].

A high percentage (97%) of ALGS patients have cardiac murmur[11,12], including branch pulmonary artery stenosis, peripheral pulmonary stenosis, tetralogy of Fallot (TOF), valvar pulmonic stenosis, atrial septal defect, ventricular septal defect, coarctation of the aorta, and similar issues[13]. To our knowledge, the association of total anomalous pulmonary venous connection (TAPVC) and ALGS has never been reported in any article, but it was reported in a conference by Sanchez-Lara *et al*[14].

**CASE PRESENTATION**

***Chief complaints***

A 20-day-old male neonate with unknown cause of jaundice since birth and TAPVC was referred to our hospital.

***History of present illness***

The patient had jaundice and TAPVC since birth, without a history of other ailments.

***History of past illness***

There was no history of past illness.

***Personal and family history***

There was no family history of other genetic diseases. The father showed characteristic facial features: A prominent forehead, deep-set eyes with mild hypertelorism, pointed chin, and saddle-shaped nose with a bulbous tip.

***Physical examination***

Physical examination revealed an infant weight of 3.2 kg. Jaundiced skin and sclera were observed along with a triangular appearance. The patient showed the same characteristic facial features as his father (Figure 1). He had abnormalities in both eyes (Figure 2) (posterior embryotoxon). No positive signs were found in the lungs. Abnormal sounds and murmurs were audible upon heart auscultation. The liver was palpable with a soft edge 4.0 cm below the right costal margin.

***Laboratory examinations***

Biochemical analysis showed increased levels of serum gamma-glutamyl transpeptidase, total bilirubin (TBil), direct bilirubin (DBil), and total bile acids (TBAs), indicating cholestasis (Table 1).

***Imaging examinations***

X-ray didn’t discover obvious skeletal deformities (Figure 3A), while Chest computed tomography (CT) angiography clearly shows that butterfly vertebra at the seventh thoracic vertebrae (Figure 3B). CT angiography showed that four pulmonary veins (PVs) joined together and drained into the vertical vein (VV). The VV flowed into the dilated left innominate vein (LIV), then into the superior vena cava (SVC), and finally into the right atrium (RA) (Figure 4).

***Further diagnostic work-up***

Based on these findings, ALGS was suspected and confirmed by genetic testing. A heterozygous variant (c.3197dupC) in the *JAG1* gene was identified (Figure 5). This is a frame shift mutation, and it has been reported previously[10]. It is expected that the protein products encoded by this gene will be cut off prematurely, which is considered pathogenic.

**FINAL DIAGNOSIS**

Based on the clinical, imaging, and genetic findings, the final diagnosis was ALGS.

**TREATMENT**

After a clear diagnosis of ALGS, the patient began ursodiol treatment, which he has been tolerating very well. The patient underwent surgical correction of his cardiac murmur at the age of 1.5 mo. He responded well to treatment and was discharged 1.5 mo later.

**OUTCOME AND FOLLOW-UP**

The patient did not attend regular follow-up visits at our hospital; thus, no follow-up data were obtained. He returned to our clinic due to severe xanthomas at the age of two years (Figure 6). Laboratory tests revealed increased levels of alanine aminotransferase, 339 U/L; aspartate aminotransferase, 396 U/L; alkaline phosphatase, 998 U/L; Tbil, 138.5 μmol/L; Dbil, 112.3 μmol/L; TBAs, 270.2 μmol/L; total cholesterol level, 39.9 mmol/L; and triglyceride levels, 3.79 mmol/L.

**DISCUSSION**

Protein Jagged-1 encoded by the *JAG1* gene is one of the ligands of the Notch receptor[1]. Notch signaling pathway plays an important role in cardiovascular development[15,16]. It coordinates the morphogenesis of the cardiac chambers and valves, and regulates the formation of the cardiac outflow tract[11,12]. Therefore, malformations related to right ventricular outflow tract obstruction (RVOTO), such as stenosis at some level of the pulmonary tree and TOF, have accounted for more than 80% of cardiac murmurs in these patients[13,16]. However, a few patients have other cardiac murmurs, such as valvar pulmonic stenosis, atrial septal defect, ventricular septal defect, patent ductus arteriosus, or double-chambered RV[16].

Our patient was confirmed to have ALGS by clinical examination and genetic testing. His cardiac murmur, TAPVC, has never been reported in any article on ALGS. TAPVC is a rare cardiac murmur in which the PVs fail to return to the RA. The incidence of this rare entity is approximately 7-9 *per* 100000 live births or 0.7%-1.5% of all congenital heart diseases[17-20]. TAPVC is divided into four major types. Type I: Supracardiac (approximately 55%), as in this case, which is the most common type. The PVs confluence behind the left atrium, then drain into the LIV through the VV, then into the SVC or sometimes into the azygos vein, and finally into the RA[17]. Type II: Intracardiac (approximately 30%), all PVs drain directly into the RA or through the common trunk of the PVs to the coronary sinus[21,22]. Type III: Infracardiac (approximately 12%), after confluence behind the LA, the PVs pass the diaphragmatic esophageal hiatus through the VV, then flow into the portal vein or its branches[21,22]. Type IV: Mixed (approximately 3%), the PVs enter the RA through multiple channels[21,22].

*JAG1* gene mutations are mainly associated with the development of RVOTO, which is a spectrum of diseases associated with the pulmonary valve, branches of the pulmonary artery, and the RV[16]. Thus, stenosis at some level of the pulmonary tree and TOF are the most common causes of cardiac murmur in ALGS patients. However, a number of other types of cardiac murmur have been discovered in ALGS patients. This indicates that *JAG1* mutations have a multifaceted impact on cardiac development. TAPVC has not been reported in ALGS patients in any article; however, Sanchez-Lara *et al*[14] reported three ALGS patients at the 2006 ASHG Annual Meeting[14]. Therefore, at least five ALGS patients and three mutation sites have been found to be associated with TAPVC. We suspect that *JAG1* is closely associated with TAPVC.

Biliary stricture is the main feature in most ALGS patients, and unusual structures can cause cholestatic liver disease. The dysfunctional liver often leads to an increase in serum total cholesterol and triglycerides. Thus, hypercholesterolemia is attributable to cholestasis and may finally lead to severe xanthomas[23]. Although some medicines have been reported to improve liver function in ALGS patients, the only way to resolve the problem is liver transplantation.

**CONCLUSION**

Bile duct paucity is the main characteristic feature in most cases of ALGS. Here, we report a more fatal and rarer feature, TAPVC, which requires surgical correction at an early age. We also report the unusual finding of severe xanthomas. These findings suggest that *JAG1* gene may be a pathogenic gene of TAPVC. Further research should be carried out to prove this hypothesis.

**REFERENCES**

1 **Oda T**, Elkahloun AG, Pike BL, Okajima K, Krantz ID, Genin A, Piccoli DA, Meltzer PS, Spinner NB, Collins FS, Chandrasekharappa SC. Mutations in the human Jagged1 gene are responsible for Alagille syndrome. *Nat Genet* 1997; **16**: 235-242 [PMID: 9207787 DOI: 10.1038/ng0797-235]

2 **McDaniell R**, Warthen DM, Sanchez-Lara PA, Pai A, Krantz ID, Piccoli DA, Spinner NB. NOTCH2 mutations cause Alagille syndrome, a heterogeneous disorder of the notch signaling pathway. *Am J Hum Genet* 2006; **79**: 169-173 [PMID: 16773578 DOI: 10.1086/505332]

3 **Tsai EA**, Gilbert MA, Grochowski CM, Underkoffler LA, Meng H, Zhang X, Wang MM, Shitaye H, Hankenson KD, Piccoli D, Lin H, Kamath BM, Devoto M, Spinner NB, Loomes KM. *THBS2* Is a Candidate Modifier of Liver Disease Severity in Alagille Syndrome. *Cell Mol Gastroenterol Hepatol* 2016; **2**: 663-675.e2 [PMID: 28090565 DOI: 10.1016/j.jcmgh.2016.05.013]

4 **Alagille D**, Odièvre M, Gautier M, Dommergues JP. Hepatic ductular hypoplasia associated with characteristic facies, vertebral malformations, retarded physical, mental, and sexual development, and cardiac murmur. *J Pediatr* 1975; **86**: 63-71 [PMID: 803282 DOI: 10.1016/s0022-3476(75)80706-2]

5 **Alagille D**, Estrada A, Hadchouel M, Gautier M, Odièvre M, Dommergues JP. Syndromic paucity of interlobular bile ducts (Alagille syndrome or arteriohepatic dysplasia): review of 80 cases. *J Pediatr* 1987; **110**: 195-200 [PMID: 3806290 DOI: 10.1016/s0022-3476(87)80153-1]

6 **Wang JS**, Wang XH, Zhu QR, Wang ZL, Hu XQ, Zheng S. Clinical and pathological characteristics of Alagille syndrome in Chinese children. *World J Pediatr* 2008; **4**: 283-288 [PMID: 19104892 DOI: 10.1007/s12519-008-0051-5]

7 **Turnpenny PD**, Ellard S. Alagille syndrome: pathogenesis, diagnosis and management. *Eur J Hum Genet* 2012; **20**: 251-257 [PMID: 21934706 DOI: 10.1038/ejhg.2011.181]

8 **Bhatia V**, Kumar P. Alagille syndrome with a previously undescribed mutation. *Indian Pediatr* 2014; **51**: 314-316 [PMID: 24825276]

9 **Jesina D**. Alagille Syndrome: An Overview. *Neonatal Netw* 2017; **36**: 343-347 [PMID: 29185945 DOI: 10.1891/0730-0832.36.6.343]

10 **Warthen DM**, Moore EC, Kamath BM, Morrissette JJ, Sanchez-Lara PA, Piccoli DA, Krantz ID, Spinner NB. Jagged1 (JAG1) mutations in Alagille syndrome: increasing the mutation detection rate. *Hum Mutat* 2006; **27**: 436-443 [PMID: 16575836 DOI: 10.1002/humu.20310]

11 **Luxán G**, D'Amato G, MacGrogan D, de la Pompa JL. Endocardial Notch Signaling in Cardiac Development and Disease. *Circ Res* 2016; **118**: e1-e18 [PMID: 26635389 DOI: 10.1161/CIRCRESAHA.115.305350]

12 **Samsa LA**, Givens C, Tzima E, Stainier DY, Qian L, Liu J. Cardiac contraction activates endocardial Notch signaling to modulate chamber maturation in zebrafish. *Development* 2015; **142**: 4080-4091 [PMID: 26628092 DOI: 10.1242/dev.125724]

13 **Wu KY**, Treece AL, Russo PA, Wen JW. An Atypical Presentation of Alagille Syndrome. *Pediatr Dev Pathol* 2018; **21**: 79-83 [PMID: 29187043 DOI: 10.1177/1093526616686902]

14 **Sanchez-Lara PA,** Krantz ID, Spinner NB. TAPVR: A Cardiac Defect Associated with Alagille syndrome. 2006 ASHG Annual Meeting. [cited 10 October 2021]. Available from: https://www.ashg.org/wp-content/uploads/2020/07/2006-allabstracts.pdf

15 **Penton AL**, Leonard LD, Spinner NB. Notch signaling in human development and disease. *Semin Cell Dev Biol* 2012; **23**: 450-457 [PMID: 22306179 DOI: 10.1016/j.semcdb.2012.01.010]

16 **McElhinney DB**, Krantz ID, Bason L, Piccoli DA, Emerick KM, Spinner NB, Goldmuntz E. Analysis of cardiovascular phenotype and genotype-phenotype correlation in individuals with a JAG1 mutation and/or Alagille syndrome. *Circulation* 2002; **106**: 2567-2574 [PMID: 12427653 DOI: 10.1161/01.cir.0000037221.45902.69]

17 **Kao CC**, Hsieh CC, Cheng PJ, Chiang CH, Huang SY. Total Anomalous Pulmonary Venous Connection: From Embryology to a Prenatal Ultrasound Diagnostic Update. *J Med Ultrasound* 2017; **25**: 130-137 [PMID: 30065477 DOI: 10.1016/j.jmu.2017.08.002]

18 **Vanderlaan RD**, Caldarone CA. Surgical Approaches to Total Anomalous Pulmonary Venous Connection. *Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu* 2018; **21**: 83-91 [PMID: 29425529 DOI: 10.1053/j.pcsu.2017.11.010]

19 **Paladini D**, Pistorio A, Wu LH, Meccariello G, Lei T, Tuo G, Donarini G, Marasini M, Xie HN. Prenatal diagnosis of total and partial anomalous pulmonary venous connection: multicenter cohort study and meta-analysis. *Ultrasound Obstet Gynecol* 2018; **52**: 24-34 [PMID: 28926132 DOI: 10.1002/uog.18907]

20 **Fu CM**, Wang JK, Lu CW, Chiu SN, Lin MT, Chen CA, Chang CI, Chen YS, Chiu IS, Wu MH. Total anomalous pulmonary venous connection: 15 years' experience of a tertiary care center in Taiwan. *Pediatr Neonatol* 2012; **53**: 164-170 [PMID: 22770104 DOI: 10.1016/j.pedneo.2012.04.002]

21 **Alam T**, Hamidi H, Hoshang MM. Computed tomography features of supracardiac total anomalous pulmonary venous connection in an infant. *Radiol Case Rep* 2016; **11**: 134-137 [PMID: 27594934 DOI: 10.1016/j.radcr.2016.04.005]

22 **Dillman JR**, Yarram SG, Hernandez RJ. Imaging of pulmonary venous developmental anomalies. *AJR Am J Roentgenol* 2009; **192**: 1272-1285 [PMID: 19380552 DOI: 10.2214/AJR.08.1526]

23 **Hannoush ZC**, Puerta H, Bauer MS, Goldberg RB. New JAG1 Mutation Causing Alagille Syndrome Presenting With Severe Hypercholesterolemia: Case Report With Emphasis on Genetics and Lipid Abnormalities. *J Clin Endocrinol Metab* 2017; **102**: 350-353 [PMID: 27967296 DOI: 10.1210/jc.2016-3171]

**Footnotes**

**Informed consent statement:** The patient’s guardian provided written informed consent to participate in this study. Written informed consent was obtained for the publication of any potentially identifiable images or data included in this article.

**Conflict-of-interest statement:** All theauthors report no relevant conflicts of interest for this article.

**CARE Checklist (2016) statement:** The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (16).

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** November 24, 2021

**First decision:** June 7, 2022

**Article in press:**

**Specialty type:** Medicine, research and experimental

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B, B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** De Raffele E, Italy; Moshref RH, Saudi Arabia **S-Editor:** Fan JR **L-Editor:** A **P-Editor:** Fan JR

**Figure Legends**



**Figure 1 The patient shows characteristic faces of Alagille syndrome: Prominent forehead, deep-set eyes, mild hypertelorism, pointed chin, and saddle shape nose with a bulbous tip.** A: Front image; B: Side image.



**Figure 2 Posterior embryotoxon.** A: Posterior embryotoxon in left eye; B: Posterior embryotoxon in right eye. L: Left; R: Right.



**Figure 3 X-ray and computed tomography examination.** A: X-ray didn’t discover obvious skeletal deformities; B: Chest computed tomography clearly showed that butterfly vertebra at the seventh thoracic vertebrae.



**Figure 4 The classic hemodynamic features of total anomalous pulmonary venous connection type I.** LIV: Left innominate vein; VV: Vertical vein; SVC: Superior vena cava.



**Figure 5 Gene analysis results of the family.** A: Next generation sequencing result of the patient; B-D: Sanger sequencing results of the patient, the mother and the father.



**Figure 6 Xanthomas seen in the surface of hands and feet.** A and B: Hands; C: Feet.

**Table 1 Biochemical alterations over time of the patient when he was in hospital**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Biochemical indices** | **February 26, 2017** | **March 5, 2017** | **March 11, 2017** | **March 20, 2017** | **March 27, 2017** | **April 3, 2017** | **April 9, 2017** |
| ALT (5-40 U/L) | 107 | 198 | 266 | 527 | 256 | 324 | 444 |
| AST (5-40 U/L) | 221 | 382 | 457 | 620 | 233 | 378 | 525 |
| GGT (8-50 U/L) | 573 |  | 1015 | 1186 | 1065 | 1125 | 1114 |
| ALP (20-500 U/L) | 440 |  | 390 | 418 | 200 | 197 | 262 |
| TP (60.0-83.0 g/L) | 55.1 | 65.1 | 60.6 | 57.7 | 45.9 | 53.3 | 52.2 |
| Alb (35.0-55.0 g/L) | 36.5 | 40.2 | 38.2 | 38.8 | 30.4 | 34.3 | 35.5 |
| Tbil (2-19 μmol/L) | 242.4 | 241.4 | 254.0 | 469.6 | 235.4 | 295.6 | 294.5 |
| Dbil (0-6 μmol/L) | 165.5 | 163.6 | 133.1 | 245.9 | 149.0 | 138.7 | 124.4 |
| Ibil (2.56-20.9 μmol/L) | 76.9 | 77.8 | 120.9 | 223.7 | 86.4 | 156.9 | 170.1 |
| TBA (0-10 μmol/L) | 100 | 116.0 | 74.0 | 104.0 | 94.0 | 113.0 | 133.3 |

ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; GGT: Gamma-glutamyl transferase; ALP: Alkaline phosphatase; TP: Total protein; Alb: Albumin; Tbil: Total bilirubin; Dbil: Direct bilirubin; Ibil: Indirect bilirubin; TBA: Total bile acid.